// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

The development and implementation of a lung health awareness programme in a rural district of Uganda

Frederik van Gemert - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The management of allergic reactions in the pre-hospital setting: Does parenteral adrenaline get used unnecessarily?>

Craig Mortimer - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Epinephrine

Comparing asthma and COPD inhaler devices in real life clinical practice in the UK: differences in training requirements and preference

Henry Chrystyn - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Asthma

DuoResp Spiromax

Assessing NHS stop smoking service engagement in community pharmacies using actors

Sandra Jumbe - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Beliefs and behaviours towards chronic lung disease - a mixed-method FRESH AIR study

Evelyn Brakema - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Living with breathlessness: a systematic literature review and thematic synthesis

Ann Hutchinson - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Assessment of impact on length of stay (LOS) and cost burden of respiratory inpatients after introduction of hospital at home(H@H) service for bronchiectasis

Ming Lim - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Estimating exacerbation rates from routine UK primary care data: an exploratory validation from the IMP2ART programme

Chris Newby - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Exploring patient and carer perspectives on asthma self-management: a qualitative study from the IMP2ART programme

Luke Daines - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Local implementation of a pathway to manage malnourished COPD patients in the community

Abbie Cawood - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Supporting COPD patients to access pulmonary rehabilitation with lay health workers: a feasibility study

Patrick T. White - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Using the methacholine challenge to determine how psychological mechanisms impact asthma symptom perception and quality of life

Ben Ainsworth - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

SK1211

Insight into frequent asthma exacerbations from a primary care perspective and the implications of UK National Review of Asthma Deaths (NRAD) recommendations

Rekha Chaudhuri - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

The distribution of COPD in UK general practice using the 2017 GOLD classification

John Haughney - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Patient and Public Involvement (PPI) in TANDEM: A Tailored intervention for ANxiety and DEpression Management in COPD

Amy Barradell - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Depression

N/A

Cardio-metabolic profile, function and physical activity in mild-moderate COPD patients

Amy Jones - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Real-life evaluation of budesonide/formoterol (DuoResp Spiromax) for the management of asthma and COPD in the UK

Nicolas Roche - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Asthma

budesonide + formoterol fuma

Patient demographics and clinical characteristics in the UK Salford Lung Study (SLS COPD) and the European ACCESS study

Maurice Driessen - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Fluticasone furoate

The lay health worker-patient partnership promoting PR in COPD: what makes it work?

Patrick T. White - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

A patient evaluation of performing COPD research in primary care

Mona Bafadhel - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Copyright © 2026. QuantiNova All rights reserved